TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18506129
Drug: Propionyl-L-carnitine (PLC)
Normalized name: glycine propionyl-L-carnitine
DrugBank: Levocarnitine propionate (DB15980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl-L-carnitine (PLC) in association with pulsed muscular compression therapy (Vascupump) for 5 sessions a week for 4 weeks
Study: 18506129
Drug: Pulsed muscular
Normalized name: Orchis mascula whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed muscular compression therapy (Vascupump) only
Study: 15898936
Drug: Systemic amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic amoxicillin plus metronidazole and CHX irrigation
Study: 15898936
Drug: Subgingival scaling
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgingival scaling without adjunctive therapy (control group)
Study: 8983866
Drug: High fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fat meal with insulin (peak insulin 86.1 ± 10.1 m-units/l)
Study: 6959168
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of methadone
Study: 31881956
Drug: Guided-care (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided-care (with gene-drug interactions)
Study: 29417694
Drug: Duloxetine (DLX,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (DLX, 60 mg once daily)
Study: 26972745
Drug: Pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill placebo and PE
Study: 15801505
Drug: Non-elaborated words
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-elaborated words (treatment group)
Study: 15801505
Drug: Elaborated words
Normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elaborated words (treatment group)
Study: 6663643
Drug: Structured couples
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured couples treatment program
Study: 29570535
Drug: Daily measurements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily measurements of vital signs, body weight, and fluid intake and output
Study: 18292445
Drug: Perioperative celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative celecoxib (2 celecoxib 200 mg p.o. 30‐90 min before surgery, and two placebos after surgery, followed by one celecoxib 200 mg p.o. BID on postoperative day #1, #2, and #3)
Study: 16548286
Drug: Dexmedetomidine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine administered prior to anesthesia
Study: 16548286
Drug: Dexmedetomidine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine administered during transanesthesia
Study: 11191783
Drug: Fluid replacement
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid replacement (200 or 250 ml of warm water at approximately 35 degrees C) during light exercise (L/F)
Study: 11191783
Drug: No fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No fluid (NF) during light exercise (L/NF)
Study: 11191783
Drug: Fluid replacement
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid replacement (F) during light exercise (L)
Study: 11191783
Drug: Fluid replacement
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid replacement during light exercise (L/F)
Study: 11191783
Drug: No fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No fluid during light exercise (L/NF)
Study: 8255440
Drug: Branched-chain amino
Normalized name: Branched-chain amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched-chain amino acids (BCAA) - L‐leucine 12 g, L‐isoleucine 6 g, L‐valine 6 g daily
Study: 3515261
Drug: Intramuscular ritodrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ritodrine followed by oral ritodrine treatment and bed rest
Study: 15333424
Drug: conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional therapy
Study: 20379004
Drug: Drug alteration
Normalized name: SLICK ALTERATION DISRUPTING BOS TAURUS G.(NC_037347.1) FS(39099129-39099368) IN EXON 9 OF PRLR GENE IN BOS TAURUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug alteration (DA) group
Study: 17943420
Drug: Nalbuphine (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (2.5, 5, 10, or 20 mg)
Study: 17943420
Drug: Naloxone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.2 or 0.4 mg, ED(50) estimated at 0.5 mg)
Study: 17943420
Drug: Nalbuphine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine and Naloxone (in combination)
Study: 2006724
Drug: midazolam/flumazenil (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam/flumazenil (15 mg midazolam, 0.5 mg flumazenil after 60 min)
Study: 23635869
Drug: Kava (120/240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kava (120/240 mg of kavalactones per day)
Study: 3018603
Drug: Enalapril (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10‐20 mg b.i.d.)
Study: 23819698
Drug: Aclidinium 400
Normalized name: aclidinium 400 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium 400 μg twice daily
Study: 20112485
Drug: 5-step manipulation
Normalized name: STEP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-step manipulation and traction (treatment group)
Study: 17484080
Drug: Intravenous indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous indomethacin (0.2 mg/kg at 12‐hour intervals)
Study: 17484080
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen suspension (10 mg/kg initial dose, followed by two doses of 5 mg/kg each after 24 and 48 hours)
Study: 19255990
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen suspension
Study: 11818602
Drug: Sedation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation with adjunct hypnosis
Study: 11818602
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous conscious sedation
Study: 30616547
Drug: BITS7201A (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: BITS7201A (150 mg SC, 300 mg SC, 600 mg SC)
Study: 10208786
Drug: Intra-aortic balloon
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-aortic balloon pump therapy
Study: 25287767
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy without intra-aortic balloon pump
Study: 28187983
Drug: Intensified therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified therapy
Study: 27911988
Drug: Mirabegron (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron (25-50 mg)
Study: 27911988
Drug: Solifenacin (2.5-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin (2.5-5 mg)
Study: 20542324
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy (OIT) using a rush protocol with roasted peanut for 7 days
Study: 16203884
Drug: Open operative
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open operative treatment
Study: 12519844
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg twice daily for 3 months, then 1000 mg twice daily for 3 months; n = 8)
Study: 10930893
Drug: Rifaximin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (400 mg b.d per 7 days)
Study: 10930893
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (400 mg b.d per 7 days)
Study: 6140440
Drug: Regular alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular alcohol consumption (up to 80 g daily)
Study: 31035190
Drug: Clonazepam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (0.5 mg/day at bedtime)
Study: 25472768
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (long/intermediate acting)
Study: 19549615
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (ELE + prolotherapy)
Study: 6173514
Drug: Phentolamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine infusion after placebo
Study: 6173514
Drug: Phentolamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine infusion after prazosin (alpha 1-blocker)
Study: 29984691
Drug: 6-monthly Periodontal
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6-monthly Periodontal Instrumentation (PI)
Study: 29984691
Drug: 12-monthly PI
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 12-monthly PI
Study: 29984691
Drug: Personalised OHA
Normalized name: 4-OHAD
DrugBank: Formestane (DB08905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalised OHA with 6-monthly PI
Study: 26679763
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA (2.2 g/day)
Study: 23077137
Drug: Sitagliptin 100-mg
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100-mg administered on Day 5 of a 7 day course of simvastatin 80-mg once daily
Study: 23077137
Drug: Sitagliptin 100-mg
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100-mg alone
Study: 20889472
Drug: Participants who
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who reported binge eating prior to or during treatment
Study: 12536245
Drug: Indirect radionuclide
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect radionuclide cystography (IRNC) using technetium‐99m diethylene triamine penta‐acetate (DTPA) with a dosage of 37 MBq/10 kg body weight.
Study: 8896777
Drug: Dim red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim red light (50 lx) for 2 hours daily for 1 week
Study: 6630409
Drug: Prior receptor
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior receptor blockade with naloxone and atropine
Study: 26660041
Drug: heparin 1000
Normalized name: HEPARIN 10000UNIT/ML CARPUJECT 0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin 1000 units/mL
Study: 20837894
Drug: Non-ICD medical
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ICD medical therapy
Study: 11856076
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole once daily
Study: 10434832
Drug: ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 4 mg i.v.
Study: 23622912
Drug: Mild CKD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild CKD (60-89 mL/min)
Study: 23622912
Drug: Moderate CKD
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate CKD (30-59 mL/min)
Study: 23622912
Drug: Severe CKD
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe CKD (<30 mL/min)
Study: 19339808
Drug: Pollen group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pollen group (received grass pollen, grass and olive pollen, or hazel, alder and birch pollen according to a 3-week titration cluster)
Study: 19339808
Drug: HDM group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM group (received HDM extract according to a 2-week titration cluster)
Study: 15053895
Drug: DPT-1 parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPT-1 parenteral trials (insulin administration)
Study: 8385230
Drug: Minimum methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimum methadone services (MMS) - methadone alone (a minimum of 60 mg/d) with no other services
Study: 3544605
Drug: Heparin-dihydroergotamine twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-dihydroergotamine twice a day
Study: 25385173
Drug: telmisartan and
Normalized name: telmisartan and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: telmisartan and atorvastatin (ARB)
Study: 950374
Drug: Insulin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.1 IU/kg BW) administered at various times (0400 h, 0800 h, 1200 h, 1600 h, 2000 h, 2400 h)
Study: 26121460
Drug: Basal-bolus regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal-bolus regimen with glargine once daily and glulisine before meals (n = 66)
Study: 26121460
Drug: NPH twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH twice daily and regular insulin before meals (n = 68)
Study: 16191910
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health program including parent education, toothbrushing instruction, and fluoride tablets (0.25 mg/day)
Study: 10655292
Drug: Medi-Jector administration
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medi-Jector administration of ganirelix (2 mg s.c. once daily for 7 days)
Study: 10655292
Drug: Conventional needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional needle injection of ganirelix (2 mg s.c. once daily for 7 days)
Study: 27742577
Drug: Controlled-release oral
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release oral morphine
Study: 18775429
Drug: Anti-Hp therapy
Normalized name: Anti-CD5 CAR T-cell therapy
DrugBank: Anti-CD5 CAR T-cell therapy (DB17279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Hp therapy plus iron (amoxicillin, clarithromycin, and omeprazole + 90-day oral ferrous sulfate)
Study: 18775429
Drug: Anti-Hp therapy
Normalized name: Anti-CD5 CAR T-cell therapy
DrugBank: Anti-CD5 CAR T-cell therapy (DB17279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Hp therapy plus iron
Study: 18775429
Drug: Anti-Hp therapy
Normalized name: Anti-CD5 CAR T-cell therapy
DrugBank: Anti-CD5 CAR T-cell therapy (DB17279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Hp therapy alone
Study: 8911832
Drug: NaHCO3 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaHCO3 (0.3 g.kg‐1 body mass)
Study: 8388090
Drug: IV cyclophosphamide/ACTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV cyclophosphamide/ACTH with outpatient IV cyclophosphamide boosters (700 mg/m2 every other month for 2 years)
Study: 3725002
Drug: Ethanol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.5 ml/kg) alone
Study: 6487494
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Ethanol (0.5 ml/kg)
Study: 3725002
Drug: Amitriptyline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (50 mg) alone
Study: 25518506
Drug: Dinitrosyl iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinitrosyl iron complex (1.5 or 3 mg/kg)
Study: 22507264
Drug: Yoga therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga therapy (suryanamaskara, asanas, pranayama, and meditation) for 1 hour per day for 12 weeks
Study: 18544464
Drug: Disease management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease management program for smoking cessation combining pharmacotherapy, telephone counseling, and physician feedback, repeated intervention over two years.
Study: 10397414
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of illness, neuroleptic medication, and negative symptoms
Study: 30531478
Drug: Cebranopadol 200
Normalized name: Cebranopadol
DrugBank: Cebranopadol (DB12830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cebranopadol 200 μg
Study: 30531478
Drug: Cebranopadol 400
Normalized name: Cebranopadol
DrugBank: Cebranopadol (DB12830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cebranopadol 400 μg
Study: 30531478
Drug: Cebranopadol 800
Normalized name: Cebranopadol
DrugBank: Cebranopadol (DB12830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cebranopadol 800 μg
Study: 2457074
Drug: Hydromorphone 8
Normalized name: HYDROmorphone 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone 8 mg
Study: 30531478
Drug: Hydromorphone 16
Normalized name: HYDROmorphone 16 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone 16 mg
Study: 24759796
Drug: Prasugrel (20/3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (20/3.75 mg)
Study: 25342212
Drug: Clopidogrel (300/75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300/75 mg)
Study: 15356662
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (average weight loss of 28 kg)
Study: 15356662
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (weight stable)
Study: 8302340
Drug: Riluzole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole (100 mg per day)
Study: 2735022
Drug: Kinetic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinetic treatment table (KTT)
Study: 1093638
Drug: Ampicillin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (two oral doses of 1 g. 5 hours apart)
Study: 30987813
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3 (500 IU/d)
Study: 26054203
Drug: Simple acupuncture
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple acupuncture therapy
Study: 18695308
Drug: Dalteparin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (low molecular-weight heparin)
Study: 2429844
Drug: Propafenone 300
Normalized name: propafenone 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 300 mg single dose
Study: 2429844
Drug: Propafenone 150
Normalized name: propafenone 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 150 mg t.i.d. multiple doses
Study: 2429844
Drug: Propafenone 150
Normalized name: propafenone 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 150 mg and 300 mg single doses
Study: 27147591
Drug: CBT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT plus modafinil (400 mg/day)
Study: 25011693
Drug: Irbesartan 300mg
Normalized name: IRBESARTAN 300MG TAB
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan 300mg daily
Study: 8695711
Drug: TPN with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN with a catheter through which antibiotic medication is administered in 'Y' (Group II)
Study: 8695711
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of infection and number of days of treatment with TPN
Study: 1505148
Drug: N-acetylcysteine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (100 mg/kg)
Study: 6702463
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (50 g) after quinidine sulfate (200 mg)
Study: 9862245
Drug: Interferon alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha‐2b (IFN) 3 million IU thrice weekly s.c. alone
Study: 9862245
Drug: Ribavirin 600
Normalized name: ribavirin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin 600 mg twice daily p.o. alone
Study: 9862245
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (IFN + ribavirin)
Study: 2146325
Drug: 13-cis retinoic
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 13-cis retinoic acid (1 mg/kg/day for 4 months)
Study: 7375893
Drug: Lillehei-Kaster (L-K)
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lillehei-Kaster (L-K) valve
Study: 29727544
Drug: Fuyang Huayu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuyang Huayu Prescription (Traditional Chinese Medicine)
Study: 29727544
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy and chemotherapy (Control)
Study: 31618812
Drug: Saffron (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron (20 mg)
Study: 28181975
Drug: Auricular acupressure
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupressure therapy (2 weeks, 2 times per week, using auricular acupressure needle on skin paper tape)
Study: 10320260
Drug: Lidocaine (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (standard antiarrhythmic dose)
Study: 3312207
Drug: Cefamandole (five
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (five doses)
Study: 3312207
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative dose of cefamandole
Study: 27432017
Drug: Hospital-to-community medication
Normalized name: zinc pyrithione Medicated Liquid Soap [Born To Be Mild]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital-to-community medication records scheme
Study: 24094767
Drug: ALN-PCS (0.400
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN-PCS (0.400 mg/kg)
Study: 17398083
Drug: 5%M+70%E/T‐gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5%M+70%E/T‐gel
Study: 17398083
Drug: 5%M/T‐gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5%M/T‐gel
Study: 17398083
Drug: 70%E/T‐gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70%E/T‐gel
Study: 17398083
Drug: T‐gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: T‐gel
Study: 11955535
Drug: Regimen A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A: zidovudine plus lamivudine starting at 36 weeks' gestation, followed by oral intrapartum dosing and by 7 days' postpartum dosing of mothers and infants.
Study: 9848308
Drug: Control slides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control slides incubated with preabsorbed antibody or mouse immunoglobulin G